Condition: Breast · Metastatic · Triple Negative · Sponsor: University of Southern California
This study looks to advance a novel and potent strategy to eliminate minimal residual disease (MRD) in triple negative breast cancer (TNBC) present even after multimodal treatment, thereby improving survival and increasing cure rate in this aggressive cancer. Patients with locally advanced TNBC are at high risk of developing lethal metastatic disease within 2 years of diagnosis, especially for those without a pathologic complete response (pCR) after neoadjuvant chemotherapy. The high risk occurs despite surgical excision of the primary tumor and axillary lymph nodes to eliminate residual disease.
This description comes directly from the study's public registry record.
Kimberly Arieli, RN · 323-865-3935 · Kimberly.Arieli@med.usc.edu
Always discuss trial participation with your own doctor first.
| Los Angeles General Medical Center | Los Angeles, California, United States | Recruiting |
| USC/Norris Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| UF Health | Gainesville, Florida, United States | Active Not Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04333706